Ambit Biosciences Corp
AMBI
AMBI was delisted on the 10th of November, 2014.
36 hedge funds and large institutions have $67M invested in Ambit Biosciences Corp in 2014 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 16 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
15% less capital invested
Capital invested by funds: $78.8M → $67M (-$11.8M)
22% less funds holding
Funds holding: 46 → 36 (-10)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
63% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aisling Capital
New York
|
+$11.6M |
| 2 |
GCM
Gruss Capital Management
New York
|
+$2.51M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.35M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$905K |
| 5 |
B
Bailard
Foster City,
California
|
+$407K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.65M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$3.35M |
| 3 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$1.57M |
| 4 |
Morgan Stanley
New York
|
-$751K |
| 5 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$648K |
AMBI Hedge Fund Activity: Q2 2014 in Review
36 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q2 2014, worth a combined $67M — down 15% from $78.8M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AMBI and 6 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 12 added.
The largest buyer was Aisling Capital, opening a new position worth an estimated $11.6M. The largest seller was Fidelity Investments, cutting an estimated $3.65M.
- 36 institutional investors held Ambit Biosciences Corp (AMBI) as of Q2 2014, down from 46 in Q1 2014.
- Funds reported $67M of Ambit Biosciences Corp stock for Q2 2014, down 15% quarter-over-quarter.
- 6 funds opened new Ambit Biosciences Corp positions in Q2 2014 and 16 closed out, a net change of -10 holders.
- The largest Ambit Biosciences Corp buyer in Q2 2014 was Aisling Capital, an estimated $11.6M added.
- The largest Ambit Biosciences Corp seller in Q2 2014 was Fidelity Investments, an estimated $3.65M sold.
Based on aggregated 13F filings for Q2 2014.